{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:26:06Z","timestamp":1770272766677,"version":"3.49.0"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Institutes of Turkey (TUSEB)"},{"name":"T\u00fcrkiye Vaccine Institute"},{"name":"Public Health General Directorate"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>TURKOVAC\u2122 is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in T\u00fcrkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administration of the vaccine as the primary or the booster dose in 15 provinces in T\u00fcrkiye. In this cohort study, between February and May 2022, in the selected 15 provinces having an adequate number of health care personnel in the community health centers to conduct the study, 32,300 people having the first, the second, or the booster dose of the vaccine were invited to the survey. A total of 29,584 people voluntarily agreed to participate to the survey and were given a structured questionnaire after a minimum of 10 days following the vaccination. In our study, only 0.5% of the participants (142 persons) reported to experience any allergic reaction, and 12 of them (8.5%) reported to be given medical treatment in a health center. Male predominance (55.6%) was observed among participants reported to experience any allergic reaction. No hospitalization was recorded. Of the participants, 4.4% (1315 people) reported to have a history of allergy. The most reported allergens were drugs. Among the participants without a known history of allergy (n = 28,269), 0.4% of them (110 people) reported to experience an allergic reaction following the vaccination, and 5.4% of the allergic reactions (six people) were reported to be treated in a health center. The percentage of the participants given any medical treatment among the participants without a known history of allergy is 0.02%. No immediate or anaphylactic reaction was reported. Among the participants with a known history of allergy (n = 1315), 32 people (2.4% of them) reported to experience an allergic reaction following the vaccination, and 18.7% of the allergic reactions (six people) were reported to be prescribed a medical treatment. The percentage of the participants given any medical treatment among the participants with a known history of allergy is 0.4%. A known history of allergy increased the risk of having an allergic experience by approximately six times following vaccination. As a whole-virion inactivated SARS-CoV-2 vaccine, the TURKOVAC\u2122 vaccine, with a low allergic reaction-related adverse event profile, can be an alternative to other COVID-19 vaccines.<\/jats:p>","DOI":"10.3390\/vaccines11020437","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:09:21Z","timestamp":1676430561000},"page":"437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC\u2122) among General and High-Risk Population"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-3232","authenticated-orcid":false,"given":"Ate\u015f","family":"Kara","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Infectious Disease Unit, Hacettepe University Faculty of Medicine, Health Institutes of T\u00fcrkiye, T\u00fcrkiye Vaccine Institute, Ankara 06100, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aslihan","family":"Coskun","sequence":"additional","affiliation":[{"name":"Health Institutes of T\u00fcrkiye, T\u00fcrkiye Vaccine Institute, Ankara 06260, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fehminaz","family":"Temel","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Ministry of Health, General Directorate of Public Health, Department of Communicable Diseases and Early Warning, Field Epidemiology Unit, Ankara 06430, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pervin","family":"\u00d6zelci","sequence":"additional","affiliation":[{"name":"Health Institutes of T\u00fcrkiye, T\u00fcrkiye Vaccine Institute, Ankara 06260, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selmur","family":"Topal","sequence":"additional","affiliation":[{"name":"T\u00fcrkiye Ministry of Health, General Directorate of Public Health, Department of Communicable Diseases and Early Warning, Field Epidemiology Unit, Ankara 06430, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130hsan","family":"Ates","sequence":"additional","affiliation":[{"name":"University of Health Science, Ankara City Hospital, Department of Internal Medicine, Ankara 06610, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref_1","unstructured":"(2023, January 30). Timeline: WHO\u2019s COVID-19 Response. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/interactive-timeline."},{"key":"ref_2","unstructured":"(2023, January 30). Coronavirus Disease (COVID-19): Vaccines. Available online: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-vaccines."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","unstructured":"(2023, January 30). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/all.14840","article-title":"Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives","volume":"76","author":"Sampath","year":"2021","journal-title":"Allergy"},{"key":"ref_6","unstructured":"(2022, November 14). Statement for Healthcare Professionals: How COVID-19 Vaccines Are Regulated for Safety and Effectiveness, Joint Statement from the International Coalition of Medicines Regulatory Authorities and World Health Organization (Revised March 2022). Available online: https:\/\/www.who.int\/news\/item\/17-05-2022-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine\u2014United States, 14\u201323 December 2020. MMWR. Morb. Mortal. Wkly. Rep., 70, 46\u201351.","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2021). Allergic Reactions Including Anaphylaxis after Receipt of the First Dose of Moderna COVID-19 Vaccine\u2014United States, 21 December 2020\u201310 January 2021. MMWR. Morb. Mortal. Wkly. Rep., 70, 125\u2013129.","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.vaccine.2022.10.093","article-title":"Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials","volume":"41","author":"Ozdarendeli","year":"2023","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tanriover, M.D., Aydin, O.A., Guner, R., Yildiz, O., Celik, I., Doganay, H.L., Kose, S., Akhan, S., Akalin, E.H., and Sezer, Z. (2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines, 10.","DOI":"10.3390\/vaccines10111865"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"878081","DOI":"10.3389\/fpubh.2022.878081","article-title":"Allergic Reactions After the Administration of COVID-19 Vaccines","volume":"10","author":"Bian","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/all.15241","article-title":"Allergies and COVID-19 vaccines: An ENDA\/EAACI Position paper","volume":"77","author":"Barbaud","year":"2022","journal-title":"Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hatmal, M.M., Al-Hatamleh, M.A.I., Olaimat, A.N., Mohamud, R., Fawaz, M., Kateeb, E.T., Alkhairy, O.K., Tayyem, R., Lounis, M., and Al-Raeei, M. (2022). Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors. Vaccines, 10.","DOI":"10.3390\/vaccines10030366"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1016\/j.jaip.2021.06.035","article-title":"Vaccine Hesitancy: Drivers and How the Allergy Community Can Help","volume":"9","author":"Turner","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/14760584.2021.1925112","article-title":"Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China","volume":"20","author":"Zhang","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_16","unstructured":"(2023, January 30). Anaphylaxis. Available online: https:\/\/www.aaaai.org\/conditions-treatments\/allergies\/anaphylaxis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100517","DOI":"10.1016\/j.waojou.2021.100517","article-title":"COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee","volume":"14","author":"Turner","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-021-00613-7","article-title":"Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis","volume":"17","author":"Alhumaid","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10875-022-01350-1","article-title":"Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program","volume":"42","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Green, M.S., Peer, V., Magid, A., Hagani, N., Anis, E., and Nitzan, D. (2022). Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines, 10.","DOI":"10.3390\/vaccines10020233"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hu, R., Peng, S., Liu, Y., Tang, F., Wang, Z., Zhang, L., Gao, J., and Guo, H. (2021). The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015\u20132018. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-11387-3"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Boland, M., Sweeney, M.R., Scallan, E., Harrington, M., and Staines, A. (2006). Emerging advantages and drawbacks of telephone surveying in public health research in Ireland and the U.K. BMC Public Health, 6.","DOI":"10.1186\/1471-2458-6-208"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:06Z","timestamp":1760121306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020437"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020437","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}